Pro-Pharmaceuticals, Inc. (OTC: PRWP), the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that the Company has been granted two new patents, "Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer" in Australia and "Selectively Depolymerized Galactomannan Polysaccharide" in the United States. These are the sixth and seventh patents in Pro-Pharmaceuticals' growing portfolio that cover its core Galectin-targeting compounds, further reinforcing our intellectual property around the world.
Pro-Pharmaceuticals' technology improves the efficacy and safety profile of chemotherapy by targeting Galectins, which are receptors directly involved in the growth, invasiveness and metastasis of cancer cells. These recently-granted patents protect methods for enhancing the efficacy while reducing the toxicity of chemotherapies in which a polysaccharide, such as the Company's lead drug candidate DAVANAT®, is co-administered with a chemotherapeutic agent. The patents also allow claims for the composition of matter for DAVANAT® itself.
"We continue to strengthen our intellectual property portfolio in the U.S. and beyond. We expect similar success with six additional patent applications pending in Europe, Japan, Brazil, and other key markets," said Anatole Klyosov, Ph.D., D.Sc., Chief Scientist, Pro-Pharmaceuticals. "Based on overwhelming data in our studies as well as third-party studies at major international laboratories, we are confident that our Galectin-targeting compounds, that is Galectin blockers, will soon play a major role in advancing the treatment of cancer and liver fibrosis."
Study shows AI can predict prognosis in triple-negative breast cancer